Advice for Healthcare Professionals The MHRA Drug Safety Update provides the following key guidance for healthcare professionals: Semaglutide treatment may be very rarely associated with NAION, which can cause vision loss, typically in one eye NAION typically presents as sudden, painless vision loss described as blurring or cloudiness Privately prescribed semaglutide may not appear on a patients medical record if a patient presents with these symptoms, enquire about semaglutide use Patients reporting sudden loss of vision (including partial loss) should be urgently referred for specialist examination by an ophthalmologist Discontinue semaglutide treatment if NAION is confirmed Advise new patients, or existing patients during medication reviews, to urgently attend eye casualty or A&E if they experience sudden vision loss or rapidly worsening eyesight An alert advised healthcare professionals to be vigilant for further issues, including rare but serious side effects such as acute pancreatitis

Leave your details and we'll get back to you shortly
THose who succeed long-term usually have support systems that help them preserve muscle, sustain behavioral change, manage side effects and navigate the psychological aspects of weight loss
Lixisenatide and exenatide have the same effect as liraglutide in AD models (84, 141, 144, 148, 157, 179, 206, 213)
If you are using one of these finished products and are desiring to heighten the GHK-Cu concentration, insert the corresponding percentage into the field named: Current GHK-Cu
During your evaluation period, try to maintain stable environmental conditions